2021
| 1) Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 2) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial | 08.03.2021 (Silvio Ragozzino) 1) Gordon A.C. et al. 2) Horby P.W. et al.: 1) Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 2) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial 1) NEJM, February 25, 2021 2) MedRxiv (preprint), February 11, 2021 |
| Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study | 01.03.2021 (Andreas Neumayr) Neumayr A. et al.: Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study |
| 1) Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England:4 June to November 2020 2) Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey 3) The contribution of nosocomial infections to the first wave | 22.02.2021 (Ana Durovic) 1) Hall V et al 2) Koen B Pouwels, Thomas House et al: 1) Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England:4 June to November 2020 2) Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey 3) The contribution of nosocomial infections to the first wave 1) medRxiv preprint: https://doi.org/10.1101/2021.01.13.21249642 2) Lancet Public Health https://doi.org/10.1016/S2468-2667(20)30282-6 3) 63.+78. SAGE meeting on COVID-19 2021 |
| Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: phase 3, randomised, controlled, non-inferiority trial | 15.02.2021 (Mihaela Sava) Maertens JA et al.: Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: phase 3, randomised, controlled, non-inferiority trial The Lancet 397 499-509 2021 |
| Interim Resukts of a Pahse 1-2a trial of Ad26.COV2.S Covid-19 Vaccine | 08.02.2021 (Anne-Valérie Burgener) J. Sadoff et al.: Interim Resukts of a Pahse 1-2a trial of Ad26.COV2.S Covid-19 Vaccine NEJM Januray 13, 2021. DOI:10.1056/NEJMoa2034201 2021 |
| Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections | 01.02.2021 (Pascal Urwyler) Marks L.R. et al.: Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections Clinical Infectious Diseases 71(10) 650–6 2020 |
| Treatment of Highly Drug-Resistant Pulmonary Tuberculosis | 18.01.2021 (Aurélien Martinez) Francesca Conradie et al.: Treatment of Highly Drug-Resistant Pulmonary Tuberculosis The New England Journal of Medicine 382 893-302 2021 |
| Antibody Status and Inicidence of SARS-CoV-2 Infection in Health Care Workers | 11.01.2021 (Sandra Zingg) Lumley S.F. et al: Antibody Status and Inicidence of SARS-CoV-2 Infection in Health Care Workers NEJM Decemeber 23, 2020 |